Literature DB >> 21221993

Pediatric oncology for the general pediatrician: introduction to the Educational series.

Koenraad K Norga.   

Abstract

Since its establishment as a pediatric subspecialty oncology has become the near exclusive domain of specialized tertiary centers. This has greatly aided progress in the field with formation of exemplary and highly focused international consortia that have continued to streamline clinical research efforts. Recently, the rate of progress in terms of further improvements in overall outcome has paradoxically slowed. Novel strategies are therefore needed to assure continued advances. On the one hand, international and global consortia of subspecialists will continue to focus on the development of much needed improved therapies for those disease groups that have not yet seen their prognosis brighten, and on the other hand, there is a trend to invest in the development of joint-care initiatives that assure cost-effective access to standard therapy for all. This will require closer involvement of the general pediatrician in certain aspects of cancer care in its broadest sense. We hope the upcoming series will aid this process by highlighting selected topics in pediatric oncology that are likely to gain even more relevance for the general pediatrician in the years to come. They include: screening strategies for cancer predisposition syndromes; molecular diagnosis and risk-adjustment of therapy for acute leukemia in childhood; an overview of new agents in clinical development; and the impact of cancer treatment on fertility and available preservation options.

Entities:  

Mesh:

Year:  2011        PMID: 21221993     DOI: 10.1007/s00431-010-1389-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

1.  All children have a right to full access to treatment for cancer.

Authors:  Tim Eden; Ching-Hon Pui; Martin Schrappe; Gianni Tognoni; Giuseppe Masera
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

Review 2.  Molecular diagnosis and risk-adjusted therapy in pediatric hematologic malignancies: a primer for pediatricians.

Authors:  Judith Frances Margolin
Journal:  Eur J Pediatr       Date:  2011-02-25       Impact factor: 3.183

Review 3.  Educational paper. The development of new therapies for pediatric oncology.

Authors:  Terzah M Horton; Stacey L Berg
Journal:  Eur J Pediatr       Date:  2010-12-30       Impact factor: 3.183

Review 4.  Advances in understanding cancer genomes through second-generation sequencing.

Authors:  Matthew Meyerson; Stacey Gabriel; Gad Getz
Journal:  Nat Rev Genet       Date:  2010-10       Impact factor: 53.242

Review 5.  Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.

Authors:  Alexis Teplick; Megan Kowalski; Jaclyn A Biegel; Kim E Nichols
Journal:  Eur J Pediatr       Date:  2011-01-06       Impact factor: 3.183

6.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

Review 7.  Randomized clinical trials in children--ethical and methodological issues.

Authors:  A D Henschel; L G Rothenberger; J Boos
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 8.  The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.

Authors:  Leslie L Robison; Gregory T Armstrong; John D Boice; Eric J Chow; Stella M Davies; Sarah S Donaldson; Daniel M Green; Sue Hammond; Anna T Meadows; Ann C Mertens; John J Mulvihill; Paul C Nathan; Joseph P Neglia; Roger J Packer; Preetha Rajaraman; Charles A Sklar; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.